Details for New Drug Application (NDA): 218232
✉ Email this page to a colleague
NDA 218232 describes FINASTERIDE AND TADALAFIL, which is a drug marketed by Zydus Lifesciences and is included in one NDA. Additional details are available on the FINASTERIDE AND TADALAFIL profile page.
The generic ingredient in FINASTERIDE AND TADALAFIL is finasteride; tadalafil. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the finasteride; tadalafil profile page.
The generic ingredient in FINASTERIDE AND TADALAFIL is finasteride; tadalafil. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the finasteride; tadalafil profile page.
Summary for 218232
| Tradename: | FINASTERIDE AND TADALAFIL |
| Applicant: | Zydus Lifesciences |
| Ingredient: | finasteride; tadalafil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 5MG;5MG | ||||
| Approval Date: | Mar 15, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
